navidea biopharmaceuticals shares were down 16 to 8 cents after the company said it plans to continue on its current path while intending to appeal potential delisting from the nyse american exchange the stock hit its 52week low of 7 cents on june 7 and is down 87 in the past 12 months director josh wilson said navidea will continue to focus on using our fix fund propel approach our strategic vision to advance navideas innovative technology to market and the delivery of value to our stockholders for navidea selling general and administrative expenses were down 36 in the first quarter of 2023 compared to the same period in 2022 the company said it is still focused on driving shareholder return through the successful completion of phase 2b and phase 3 clinical trials this includes sourcing efficient capital to expand and deliver innovative technology and drug applications to the market